Abraxis BioScience to acquire Pfizer manufacturing complex

By Lisa Kerner

Erie, Pa., April 25 - Abraxis BioScience, Inc. said it has agreed to buy Pfizer Inc.'s Cruce Davila manufacturing facility in Barceloneta, Puerto Rico.

The 56-acre site consists of a 172,000-square-foot validated manufacturing plant with capabilities of producing EU- and U.S.-compliant injectable pharmaceuticals, protein-based biologics and metered dosed inhalers, according to a news release.

Abraxis will acquire a state-of-the-art, computer-controlled 90,000-square-foot active pharmaceutical ingredients manufacturing plant and two support facilities with laboratories, totaling 262,000 square feet as part of the deal. The company said this facility, expected to employ around 400 to 500 people, will produce chemotherapeutics such as Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).

Under the agreement, Abraxis will lease the chemical raw material plant back to Pfizer to continue the manufacturing of Pfizer's celecoxib, the active ingredient of Celebrex.

This latest acquisition adds to Abraxis' manufacturing capacity in Melrose Park, Ill., Grand Island, N.Y., and Barbengo, Switzerland.

Abraxis can now manufacture products in diverse dosage forms such as vials, bag-fill, pre-filled syringe, lyophilized, powder-fill, liquid-fill (aseptically filled and terminally sterilized) and metered dose inhalers for both the U.S. and European markets.

Abraxis is a Los Angeles-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.